Synergy Pharmaceuticals Inc.’s (SGYP) supplemental New Drug Application for TRULANCE for the treatment of adults with irritable bowel syndrome with constipation is under FDA review, with a decision expected on January 24, 2018.TRULANCE, a once-daily tablet, is already approved by the FDA for the treatment of adults with chronic idiopathic constipation.Launched in March 2017, TRULANCE has generated sales of $7.42 million so far for the first nine months ended September 30, 2017.H.C. Wainwright analyst Ram Selvaraju now expects TRULANCE to register sales of $17.5 million this year, down from his previous forecast of $27.7 million.SGYP closed Tuesday’s (Dec.26) trading at $2.24, down 1.75%.